I've worked closely with Ron for the last 3 years during the launch of a technology startup, and found him to be an invaluable resource in licensing, intellectual property and the negotiation of strategic agreements. Ron is quick on the uptake, extremely time-efficient and a real pleasure to work with on a regular basis. His rapid personal attention to matters large and small is a welcome contrast to many large firms, as is his economical cost structure.

Leigh Anderson, PhD
Leigh Anderson, PhD
CEO of SISCAPA Assay Technologies
Founder and CEO Plasma Proteome Institute
Former CSO and CEO at Large Scale Biology Corp.
Former Board Member Dade Behring Holdings (later acquired by Siemens Healthcare)

Mr. Kamis has been my patent attorney since 2008. I have found Ron to be extremely attentive, knowledgeable and a pleasure to work with. I am an entrepreneur and run several businesses and Ron has always worked around my hectic schedule and provided me with advice that is to the point, concise, cost-effective and relevant to my core business objectives. Also, I have found Ron to be very efficient which has resulted in fees that I have found quite reasonable for the services he provides.

Ron Bowsher, PhD
Ron Bowsher, PhD
CEO Reed Immunodiagnostics LLC
President B2S Consulting
Chief Scientific Officer B2S Labs
Senior Research Advisor, AIT Bioscience
Former Chief Scientist, Millipore Corp. BioPharma Services Division

I have known Ron professionally for close to 20 years and have found him to be a top-tier licensing and patent attorney in the life sciences field. I have found Ron to be creative, strategic, and able to translate complex legal and technology issues into practical, business-minded legal advice.

Colin Sandercock, Esq.
Colin Sandercock, Esq.
Partner, Perkins Coie LLP
Recognized as an "IP Star" by Managing IP (2013)
"Life Science Star" by LMG LIfe Sciences (2013)

After many years as a successful therapeutic antibody technology company, MorphoSys made efforts to expand its clinical development pipeline. In order to do this, we considered in-licensing compounds and adding additional own development programs. Over years we evaluated and continue to evaluate hundreds of programs and targets, and in doing so completed many freedom to operate analyses. Ron Kamis’s support allowed us to complete a high throughput of evaluations. In fact, Ron’s team evaluated over 40 antigens over the span of a few years, and every time he provided a high quality, high value work product, within the agreed upon timelines. Ron was always reliable and accessible, and we appreciate his valuable service.

Paul F. Wiegel, J.D., LL.M.
Paul F. Wiegel, J.D., LL.M.
Director, Intellectual Property, MorphoSys AG
U.S. Patent Attorney


Results depend upon a variety of factors unique to each case. Prior results do not guarantee or predict a similar result in any future case.